In a historic breakthrough for targeted protein degradation, Bristol Myers Squibb has secured the first FDA approval for a CELMoD therapy, with clearance of Zenbexus (iberdomide) as part of a ...

With the European Union formally reversing its marketing authorization for rare disease med Tavneos last week, regulators from the bloc are laying out their concerns on the data backing the complement ...

Having spent 14 years building out its capacity, Regeneron Genetics Center—the genomic research branch of the Tarrytown, New ...

AstraZeneca’s newly approved, first-in-class hypertension drug Baxfendy does not clear the bar for effectiveness relative to its price, according to the Institute for Clinical and Economic Review ( | ...

With its reserves depleted, a debt payment due in four weeks and its cash runway stretching only into next month, the ...

Roughly a year and a half after the approval of Vykat XR, a group of clinicians with deep ties to the Prader-Willi syndrome (PWS) community is flagging potential safety concerns about the rare disease ...

Pushing back on the concept that there can only be one victor among branded obesity drugmakers, Novo Nordisk CEO Mike Doustdar thinks that investors aren’t seeing the whole picture. | As the massive ...

Abbott will award $1 million to the school with the most donations to support student or community health. The second season of the competition ended in December, when the University of Wisconsin’s ...

With all the fretting from the pharmaceutical industry about competition from China, patent protection losses, price reduction initiatives and other government measures with the potential to hit pr | ...

Eli Lilly’s experimental weight-loss drug retatrutide has yet to be approved by the FDA. | Eli Lilly has filed lawsuits against six U.S. companies, accusing them of selling illegal versions of its ...

More than four years after its CAR-T star Carvykti’s initial FDA approval, Legend Biotech has reached a major milestone, posting its first profitable quarter. | Legend Biotech's interim CEO, Alan Bash ...

Fresenius Kabi is yanking a batch of another product in the U.S., shortly after initiating a separate recall tied to mislabeled pain medicine. | Shortly after initiating a separate recall tied to ...